Novavax Gets Competitive Shot As Third ’23-’24 COVID-19 Vaccine Provider In US
After long lagging behind Pfizer/BioNTech and Moderna, authorization of its XBB.1.5 variant-based vaccine may give Novavax a boost as an mRNA alternative could be more appealing to some. But unlike its competitors it does not have a pediatric indication.
You may also be interested in...
The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination.
CDC’s universal recommendation for XBB COVID vaccines means that Novavax’s protein-based vaccine can enter the market immediately upon FDA authorization, but some final questions from the agency are keeping the review going.
FDA approval was swiftly followed by CDC advisory committee recommendation of the XBB.1.5. variant-based vaccines for all people aged 6 months and older.